<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225079</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0103_PERFORM</org_study_id>
    <nct_id>NCT03225079</nct_id>
  </id_info>
  <brief_title>PERFORM = Pentaglobin® Registry For Outcome Report and Monitoring</brief_title>
  <acronym>PERFORM</acronym>
  <official_title>PERFORM = Pentaglobin® Registry For Outcome Report and Monitoring, International Registry on the Use of Pentaglobin® in Patients With Severe Bacterial Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International registry on the use of Pentaglobin® in patients with severe bacterial&#xD;
      infections; multicentric, international registry, non-interventional trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the Pentaglobin® registry of adult critically ill patients with severe infections is&#xD;
      primarily to assess the effects of IVIgAM on the aforementioned outcome parameters and its&#xD;
      side effects under real-life conditions based on a prospective, high-quality data&#xD;
      documentation&#xD;
&#xD;
        -  Age ≥ 18 years&#xD;
&#xD;
        -  Diagnosis of severe bacterial infection&#xD;
&#xD;
        -  Pentaglobin® use&#xD;
&#xD;
        -  signed informed consent for data collection&#xD;
&#xD;
      Exclusion criteria None&#xD;
&#xD;
      Primary endpoints&#xD;
&#xD;
        -  Comparison APACHE II and SAPS II predicted mortality vs. observed hospital mortality and&#xD;
&#xD;
        -  Difference in SOFA scores, baseline vs. posttreatment (24 h after last application)&#xD;
           assessment&#xD;
&#xD;
      Secondary endpoints&#xD;
&#xD;
        -  In-hospital mortality total and in subgroups according to baseline IgM serum levels (&lt;&#xD;
           80 mg/dL vs. ≥ 80 mg/dL) and baseline CRP (&lt; 70 mg/L vs. ≥ 70 mg/L)&#xD;
&#xD;
        -  Change in MOF score from the day before treatment start till 24 h after last application&#xD;
           of Pentaglobin&#xD;
&#xD;
        -  Course of laboratory markers (concentration-difference): CRP, procalcitonin, IL-6, IgM,&#xD;
           IgA, IgG before treatment start till 24 h after last application as far as available in&#xD;
           the centers&#xD;
&#xD;
        -  Duration of ICU stay (days)&#xD;
&#xD;
        -  Duration of hospital stay (days)&#xD;
&#xD;
        -  Time from onset of severe bacterial infection to start of treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruiting&#xD;
  </why_stopped>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Actual">October 29, 2020</completion_date>
  <primary_completion_date type="Actual">October 29, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>APACHE II and SAPS II predicted mortality vs. observed hospital mortality and</measure>
    <time_frame>up to 6 months</time_frame>
    <description>predicted mortality vs. observed hospital mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>difference in SOFA scores, baseline vs. posttreatment (24 hours after last application) assessment</measure>
    <time_frame>baseline and 24 hours after last application of Pentaglobin</time_frame>
    <description>change in SOFA scores, baseline vs. posttreatment (24 hours after last application)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality total and in subgroups according to baseline IgM serum levels and baseline CRP</measure>
    <time_frame>up to 6 months</time_frame>
    <description>In-hospital mortality total and in subgroups according to baseline IgM serum levels and baseline CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MOF score from the day before treatment start till 24 hours after last application of Pentaglobin</measure>
    <time_frame>period between baseline and 24 hours after last application of Pentaglobin</time_frame>
    <description>Change in MOF score from the day before treatment start till 24 hours after last application of Pentaglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of laboratory markers (concentration-difference): CRP, procalcitonin, IL-6, IgM, IgA, IgG before treatment start till 24 h after last application as far as available in the centers</measure>
    <time_frame>period between baseline and 24 hours after last application of Pentaglobin</time_frame>
    <description>IL-6, IgM, IgA, IgG before treatment start till 24 hours after last application as far as available in the centers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay (days)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Duration of ICU stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay (days)</measure>
    <time_frame>up to one year</time_frame>
    <description>Duration of hospital stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from onset of severe bacterial infection to start of treatment</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Time from onset of severe bacterial infection to start of treatment</description>
  </secondary_outcome>
  <enrollment type="Actual">56</enrollment>
  <condition>Severe Bacterial Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The recruitment will be primarily based on a severe bacterial infection of a patient and&#xD;
        the following application of Pentaglobin®.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age ≥ 18 years&#xD;
&#xD;
          -  Diagnosis of severe bacterial infection&#xD;
&#xD;
          -  Pentaglobin® use&#xD;
&#xD;
          -  signed informed consent for data collection -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank M Brunkhorst, Prof.Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Jena University Hospital, Center for Clinical Studies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sirio Libanes</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Erasmo Meoz</name>
      <address>
        <city>Cúcuta</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Neurology</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erzgebirgsklinikum Annaberg</name>
      <address>
        <city>Annaberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikums Gießen &amp; Marburg (UKGM)</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atatürk University Medical Faculty Trainer Hospital</name>
      <address>
        <city>Erzurum</city>
        <zip>24240</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eskişehir Osmangazi üniversitesi tıp fakültesi hastanesi</name>
      <address>
        <city>Eskişehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pentaglobin® use</keyword>
  <keyword>severe bacterial infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

